REG - AstraZeneca PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

28/03/2017 16:05

RNS Number : 7876A
AstraZeneca PLC
28 March 2017
28 March 2017 16:00 BST
TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse Regulation
AstraZeneca PLC (the Company) announces that, on 28 March 2017, awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) and of American Depositary Shares (ADSs) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP). Two ADSs are equivalent to one Ordinary Share.
The AZDBP award was granted on 28 March 2014, following the deferral of a portion of each PDMR's annual bonus paid in respect of 2013 performance into Ordinary Shares or ADSs, and vested on completion of the three-year holding period.
The AZPSP award was granted on 28 March 2014. Following the application of performance measures specified at the time of grant, 92% of the AZPSP vested and the remaining unvested part immediately and irrevocably lapsed.
Following the withholding of shares to satisfy certain tax obligations arising on vesting, the PDMRs' beneficial interests in Ordinary Shares and ADSs changed as detailed in the table below:
PDMR
Ordinary Shares acquired under the AZDBP
ADSs acquired under the AZDBP
Ordinary Shares acquired under the AZPSP
ADSs acquired under the AZPSP
Pascal Soriot
14,209

101,584

Marc Dunoyer
1,419

25,478

Mark Mallon

620

22,000
For tax purposes, the fair market value of an Ordinary Share at vest was 4974.5 pence and the fair market value of an ADS at vest was $31.80, being the relevant closing prices on the last trading day preceding the vesting day.
Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.comand follow us on Twitter @AstraZeneca.
Media Enquiries
Esra Erkal-Paler
UK/Global
+44 203 749 5638
Vanessa Rhodes
UK/Global
+44 203 749 5736
Karen Birmingham
UK/Global
+44 203 749 5634
Rob Skelding
UK/Global
+44 203 749 5821
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677
Investor Relations


Thomas Kudsk Larsen
+44 203 749 5712
Craig Marks
Finance, Fixed Income, M&A
+44 7881 615 764
Henry Wheeler
Oncology
+44 203 749 5797
Mitchell Chan
Oncology
+1 240 477 3771
Lindsey Trickett
Cardiovascular & Metabolic Diseases
+1 240 543 7970
Nick Stone
Respiratory
+44 203 749 5716
Christer Gruvris
Autoimmunity, Neuroscience & Infection
+44 203 749 5711
US toll free

+1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC
1 
Details of the person discharging managerial responsibilities / person closely associated 
a)
Name 
Pascal Soriot
2 
Reason for the notification 
a) 
Position/status 
Chief Executive Officer
b)
Initial notification /Amendment
Initial notification
3 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a) 
Name 
AstraZeneca PLC
b) 
LEI 
PY6ZZQWO2IZFZC3IOL08
4i
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a) 
Description of the financial instrument, type of instrument 
Identification code 
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
b) 
Nature of the transaction 
Acquisition of ordinary shares pursuant to vestings under the AstraZeneca Deferred Bonus Plan and the AstraZeneca Performance Share Plan, for nil consideration.
c) 
Price(s) and volume(s) 
Price(s)
Volume(s)
0
115,793
d) 
Aggregated information 
- Aggregated volume 
- Price 
Not applicable - single transaction
e) 
Date of the transaction 
28 March 2017
f) 
Place of the transaction 
Outside a trading venue
1 
Details of the person discharging managerial responsibilities / person closely associated 
a)
Name 
Marc Dunoyer
2 
Reason for the notification 
a) 
Position/status 
Chief Financial Officer
b)
Initial notification /Amendment
Initial notification
3 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a) 
Name 
AstraZeneca PLC
b) 
LEI 
PY6ZZQWO2IZFZC3IOL08
4i 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a) 
Description of the financial instrument, type of instrument 
Identification code 
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
b) 
Nature of the transaction 
Acquisition of ordinary shares pursuant to vestings under the AstraZeneca Deferred Bonus Plan and the AstraZeneca Performance Share Plan, for nil consideration.
c) 
Price(s) and volume(s) 
Price(s)
Volume(s)
0
26,897
d) 
Aggregated information 
- Aggregated volume 
- Price 
Not applicable - single transaction
e) 
Date of the transaction 
28 March 2017
f) 
Place of the transaction 
Outside a trading venue
1 
Details of the person discharging managerial responsibilities / person closely associated 
a)
Name 
Mark Mallon
2 
Reason for the notification 
a) 
Position/status 
Person Discharging Managerial Responsibilities
b)
Initial notification /Amendment
Initial notification
3 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a) 
Name 
AstraZeneca PLC
b) 
LEI 
PY6ZZQWO2IZFZC3IOL08
4i 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a) 
Description of the financial instrument, type of instrument 
Identification code 
AstraZeneca PLC American Depositary Shares
CUSIP: 046353108
b) 
Nature of the transaction 
Acquisition of ADSs pursuant to vestings under the AstraZeneca Deferred Bonus Plan and the AstraZeneca Performance Share Plan, for nil consideration.
c) 
Price(s) and volume(s) 
Price(s)
Volume(s)
0
22,620
d) 
Aggregated information 
- Aggregated volume 
- Price 
Not applicable - single transaction
e) 
Date of the transaction 
28 March 2017
f) 
Place of the transaction 
Outside a trading venue

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHUWSORBNAOUAR